SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NexStar Pharm(NXTR)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (249)12/10/1997 9:05:00 PM
From: Miljenko Zuanic  Read Replies (1) of 328
 
Peter:

>>Nothing that looked too spectacular to me. I guess that the reduced neprotoxicity is going to be their strongest selling point.<<

I guess it is not to spectacular, but it is of significance. If you pass trough data from BC report (July 17, 97), other AmBisome trials data, and today data it is visible that:
1. AmBisome is more efficient for proved fungal infection in overall study for FUO and *regular* systemic fungal infection (with excalated AmBisome dose, trial which is Fujisawa conducting),
2. AmBisome is equally efficient for proven and presumed fungal infection in overall study for FUO,
3. Ambisome is significantly more efficient in supresing emergent fungal infection in BMT sub-group,
4. Ambisome have significant lower toxicity profile in any study.

This data and data from other AmBisome clinical trials show that AmBisome is better drug (efficiency and toxicity) in any systemic fungal infection and is effective in prophylactic/systemic therapy for febrile neutropenia patients. It is not spectacular but it is significantly better than Ampho.B.

Contrary, Abelcet and in some case Amphotec (FUO) never come close to Ampho.B efficiency. No surprise EU know what they are baying. Hope US will follow EU trend. :)

Contrary to all this, stock price do not follow drug clinical data trend. Hope it will follow sales trend.

mz
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News